Jordyn Silverstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jordyn Silverstein has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Katherine Van Loon
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
13 shared publications - Ally Mwanga
Department of Surgery, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania
12 shared publications - Amie Radenbaugh
NantOmics/NantHealth, Inc., El Segundo, California
12 shared publications - Andrew J. Sedgewick
Tempus AI, Chicago, IL 60654, USA
12 shared publications - Beatrice Paul Mushi
Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
12 shared publications - Bongani Kaimila
UNC Project-Malawi, Lilongwe, Malawi
12 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Springer Nature in Journal of Cancer Education
- p. 1-11
Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study
Purpose. Although hematology/oncology (H/O) topics are essential for clinicians, many internal medicine (IM) residents perceive inadequate H/O education. This perception may be due to the lack of a standardized H/O curriculum. To address this gap, we aimed to achieve consensus about the most important H/O topics for IM residents to learn. Methods. In 2023, we conducted a 2-round modified Delphi study of IM generalists and H/O specialists at the University of California, San Francisco and Stanford University. In round 1, participants rated the importance of H/O topics on a 5-point scale (1 = very unimportant; 5 = very important). In round 2, participants viewed their own ratings vs. the group mean and could change their ratings. We used a content validity index (CVI, the percentage of respondents who rated the topic ≥ 4) of ≥ 75% to identify the most important topics. We calculated the effect sizes of between-group rating differences using Cohen’s d. Results. The round 1 and 2 response rates were 70% (92/132) and 77% (71/92), respectively. Ninety-one of the 239 topics met the CVI threshold (41 classical hematology, 14 malignant hematology, and 36 solid oncology), of which only 4 out of 91 (4%) had a large effect size, indicating agreement between generalists and specialists. There were 14 topics with a CVI of 100%, including deep venous thrombosis/pulmonary embolism, iron deficiency anemia, advance care planning, and management of end-of-life issues. Conclusion. With input from IM generalists and H/O specialists, we identified the most important H/O topics for IM residents, which can guide curriculum development.
- 30 June 2026
- Published by Springer Nature in Journal of Cancer Education
- p. 1-11
Open AccessOptimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study
Purpose. Although hematology/oncology (H/O) topics are essential for clinicians, many internal medicine (IM) residents perceive inadequate H/O education. This perception may be due to the lack of a standardized H/O curriculum. To address this gap, we aimed to achieve consensus about the most important H/O topics for IM residents to learn. Methods. In 2023, we conducted a 2-round modified Delphi study of IM generalists and H/O specialists at the University of California, San Francisco and Stanford University. In round 1, participants rated the importance of H/O topics on a 5-point scale (1 = very unimportant; 5 = very important). In round 2, participants viewed their own ratings vs. the group mean and could change their ratings. We used a content validity index (CVI, the percentage of respondents who rated the topic ≥ 4) of ≥ 75% to identify the most important topics. We calculated the effect sizes of between-group rating differences using Cohen’s d. Results. The round 1 and 2 response rates were 70% (92/132) and 77% (71/92), respectively. Ninety-one of the 239 topics met the CVI threshold (41 classical hematology, 14 malignant hematology, and 36 solid oncology), of which only 4 out of 91 (4%) had a large effect size, indicating agreement between generalists and specialists. There were 14 topics with a CVI of 100%, including deep venous thrombosis/pulmonary embolism, iron deficiency anemia, advance care planning, and management of end-of-life issues. Conclusion. With input from IM generalists and H/O specialists, we identified the most important H/O topics for IM residents, which can guide curriculum development.
- Open Access
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2614557
Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery
This cohort study evaluates the incidence of cataract surgery among patients receiving mirvetuximab soravtansine to treat ovarian cancer.
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2614557
Open AccessMirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery
This cohort study evaluates the incidence of cataract surgery among patients receiving mirvetuximab soravtansine to treat ovarian cancer.
- Open Access
- 18 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Oncofertility patterns after the overturn of Roe v Wade
The 2022 US Supreme Court decision Dobbs v Jackson Women’s Health Organization raised concerns about access to fertility care for patients with cancer, yet there is limited evidence of its real-world impact. We conducted a national survey of National Comprehensive Cancer Network member institutions to evaluate changes in fertility preservation access and utilization in the 24 months following Dobbs. Of 33 institutions surveyed, 24 (72.7%) responded. Most (83.3%) institutions reported that reproductive care remained a clinical priority, and 62.5% reported increased fertility preservation utilization. Nearly all respondents reported stable or expanded institutional resources and staffing to support oncofertility services. Institutions in less restrictive states appeared to absorb increased demand, however notable nonresponse from institutions in restrictive policy environments limited our findings. This study suggests relative resilience among academic cancer centers but highlights the need for further study to ensure equitable access to fertility preservation in the post-Dobbs era.
- 18 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Open AccessOncofertility patterns after the overturn of Roe v Wade
The 2022 US Supreme Court decision Dobbs v Jackson Women’s Health Organization raised concerns about access to fertility care for patients with cancer, yet there is limited evidence of its real-world impact. We conducted a national survey of National Comprehensive Cancer Network member institutions to evaluate changes in fertility preservation access and utilization in the 24 months following Dobbs. Of 33 institutions surveyed, 24 (72.7%) responded. Most (83.3%) institutions reported that reproductive care remained a clinical priority, and 62.5% reported increased fertility preservation utilization. Nearly all respondents reported stable or expanded institutional resources and staffing to support oncofertility services. Institutions in less restrictive states appeared to absorb increased demand, however notable nonresponse from institutions in restrictive policy environments limited our findings. This study suggests relative resilience among academic cancer centers but highlights the need for further study to ensure equitable access to fertility preservation in the post-Dobbs era.
- Open Access
- 17 April 2026
- Published by Elsevier in SSRN Electronic Journal
Phase II Study of Abemaciclib Combined with Endocrine Therapy in Low-Grade Serous Ovarian Cancer and Estrogen Receptor–Positive Endometrial Cancer
OBJECTIVE: Given the high frequency of estrogen receptor (ER) expression and dysregulation of the CDK4/6 pathway in endometrial (EC) and ovarian cancer (OC), we studied the combination of the CDK4/6 inhibitor abemaciclib with endocrine therapy in recurrent EC and OC.METHODS: This open-label, single arm, phase II study enrolled women with measurable, recurrent ER–positive EC, low grade serous OC (LGSOC), and select patients with high grade serous OC (HGSOC) with CDK4/6 pathway activation features. Patients received abemacilib 150mg orally twice daily with endocrine therapy. The primary end point was 24-week progression free survival rate (24-week PFS). Secondary endpoints were objective response rates (ORR), progression free survival (PFS), clinical benefit rate (CBR), and safety.RESULTS: Of 50 screened patients, 43 were enrolled and treated (21 EC, 14 LGSOC, 8 HGSOC). The 24-week PFS rate was 56.1% (95% CI 34.5–77.7) in EC patients and 71.4% (47.8-95.1) in LGSOC patients. The ORR was 21% in EC and 14% in LGSOC patients. The median PFS was 9.0 months (95% CI 2.4–11.3) in EC and 17.5 months (3.5-NR) in LGSOC patients. Among EC patients, median PFS in those with NSMP subtype was significantly longer compared to other molecular profiles (10.4 (95% CI 2.4-21.0) versus 1.9 (1.7-9.3) months; p=0.02). Limited clinical activity was seen in select patients with HGSOC, with CDK4/6 pathway–activating alterations.CONCLUSIONS : Abemaciclib with endocrine therapy demonstrated meaningful clinical activity in LGSOC and ER–positive EC, particularly the NSMP subtype. This combination represents a promising therapeutic option warranting further study.
- 17 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPhase II Study of Abemaciclib Combined with Endocrine Therapy in Low-Grade Serous Ovarian Cancer and Estrogen Receptor–Positive Endometrial Cancer
OBJECTIVE: Given the high frequency of estrogen receptor (ER) expression and dysregulation of the CDK4/6 pathway in endometrial (EC) and ovarian cancer (OC), we studied the combination of the CDK4/6 inhibitor abemaciclib with endocrine therapy in recurrent EC and OC.METHODS: This open-label, single arm, phase II study enrolled women with measurable, recurrent ER–positive EC, low grade serous OC (LGSOC), and select patients with high grade serous OC (HGSOC) with CDK4/6 pathway activation features. Patients received abemacilib 150mg orally twice daily with endocrine therapy. The primary end point was 24-week progression free survival rate (24-week PFS). Secondary endpoints were objective response rates (ORR), progression free survival (PFS), clinical benefit rate (CBR), and safety.RESULTS: Of 50 screened patients, 43 were enrolled and treated (21 EC, 14 LGSOC, 8 HGSOC). The 24-week PFS rate was 56.1% (95% CI 34.5–77.7) in EC patients and 71.4% (47.8-95.1) in LGSOC patients. The ORR was 21% in EC and 14% in LGSOC patients. The median PFS was 9.0 months (95% CI 2.4–11.3) in EC and 17.5 months (3.5-NR) in LGSOC patients. Among EC patients, median PFS in those with NSMP subtype was significantly longer compared to other molecular profiles (10.4 (95% CI 2.4-21.0) versus 1.9 (1.7-9.3) months; p=0.02). Limited clinical activity was seen in select patients with HGSOC, with CDK4/6 pathway–activating alterations.CONCLUSIONS : Abemaciclib with endocrine therapy demonstrated meaningful clinical activity in LGSOC and ER–positive EC, particularly the NSMP subtype. This combination represents a promising therapeutic option warranting further study.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S2. Expression of Mutsig CV genes in cohorts from Tanzania (Panel A) and Malawi (Panel B).
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S2. Expression of Mutsig CV genes in cohorts from Tanzania (Panel A) and Malawi (Panel B).
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S1. Measurement of RNA Quantity and Quality using PAXgene tissue container vs. RNAlater.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S1. Measurement of RNA Quantity and Quality using PAXgene tissue container vs. RNAlater.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Background:Esophageal squamous cell carcinoma (ESCC) comprises 90% of all esophageal cancer cases globally and is the most common histology in low-resource settings. Eastern Africa has a disproportionately high incidence of ESCC.Methods:We describe the genomic profiles of 61 ESCC cases from Tanzania and compare them to profiles from an existing cohort of ESCC cases from Malawi. We also provide a comparison to ESCC tumors in The Cancer Genome Atlas (TCGA).Results:We observed substantial transcriptional overlap with other squamous histologies via comparison with TCGA PanCan dataset. DNA analysis revealed known mutational patterns, both genome-wide as well as in genes known to be commonly mutated in ESCC. TP53 mutations were the most common somatic mutation in tumors from both Tanzania and Malawi but were detected at lower frequencies than previously reported in ESCC cases from other settings. In a combined analysis, two unique transcriptional clusters were identified: a proliferative/epithelial cluster and an invasive/migrative/mesenchymal cluster. Mutational signature analysis of the Tanzanian cohort revealed common signatures associated with aging and cytidine deaminase activity (APOBEC) and an absence of signature 29, which was previously reported in the Malawi cohort.Conclusions:This study defines the molecular characteristics of ESCC in Tanzania, and enriches the Eastern African dataset, with findings of overall similarities but also some heterogeneity across two unique sites.Impact:Despite a high burden of ESCC in Eastern Africa, investigations into the genomics in this region are nascent. This represents the largest comprehensive genomic analysis ESCC from sub-Saharan Africa to date.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Background:Esophageal squamous cell carcinoma (ESCC) comprises 90% of all esophageal cancer cases globally and is the most common histology in low-resource settings. Eastern Africa has a disproportionately high incidence of ESCC.Methods:We describe the genomic profiles of 61 ESCC cases from Tanzania and compare them to profiles from an existing cohort of ESCC cases from Malawi. We also provide a comparison to ESCC tumors in The Cancer Genome Atlas (TCGA).Results:We observed substantial transcriptional overlap with other squamous histologies via comparison with TCGA PanCan dataset. DNA analysis revealed known mutational patterns, both genome-wide as well as in genes known to be commonly mutated in ESCC. TP53 mutations were the most common somatic mutation in tumors from both Tanzania and Malawi but were detected at lower frequencies than previously reported in ESCC cases from other settings. In a combined analysis, two unique transcriptional clusters were identified: a proliferative/epithelial cluster and an invasive/migrative/mesenchymal cluster. Mutational signature analysis of the Tanzanian cohort revealed common signatures associated with aging and cytidine deaminase activity (APOBEC) and an absence of signature 29, which was previously reported in the Malawi cohort.Conclusions:This study defines the molecular characteristics of ESCC in Tanzania, and enriches the Eastern African dataset, with findings of overall similarities but also some heterogeneity across two unique sites.Impact:Despite a high burden of ESCC in Eastern Africa, investigations into the genomics in this region are nascent. This represents the largest comprehensive genomic analysis ESCC from sub-Saharan Africa to date.
- Open Access
- 28 July 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (10) , 102028
Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer
- 28 July 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (10) , 102028
Open AccessPhase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer
- Open Access
- 12 June 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (17) , 2143-2153
Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer
Mirvetuximab soravtansine (MIRV) is FDA-approved for platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression. In the MIRASOL trial, MIRV improved median progression-free survival (5.6 vs. 3.9 months) and overall survival (16.5 vs. 12.8 months; HR 0.67) over chemotherapy. MIRV has a favorable safety profile but is associated with unique ADC-related toxicities, including blurred vision, keratopathy, and nausea. Ocular side effects are managed with regular eye exams and prophylactic drops, with no permanent damage reported. MIRV has also shown promising results in combination with bevacizumab and with carboplatin in platinum-sensitive disease. Ongoing research aims to optimize ADC components and explore synergistic combinations to expand MIRV's role in FRα-expressing ovarian cancer.
- 12 June 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (17) , 2143-2153
Open AccessMirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer
Mirvetuximab soravtansine (MIRV) is FDA-approved for platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression. In the MIRASOL trial, MIRV improved median progression-free survival (5.6 vs. 3.9 months) and overall survival (16.5 vs. 12.8 months; HR 0.67) over chemotherapy. MIRV has a favorable safety profile but is associated with unique ADC-related toxicities, including blurred vision, keratopathy, and nausea. Ocular side effects are managed with regular eye exams and prophylactic drops, with no permanent damage reported. MIRV has also shown promising results in combination with bevacizumab and with carboplatin in platinum-sensitive disease. Ongoing research aims to optimize ADC components and explore synergistic combinations to expand MIRV's role in FRα-expressing ovarian cancer.
- Open Access
- 4 November 2024
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 37 (1) , 5-15
Antibody–drug conjugates as targeted therapy for treating gynecologic cancers: update 2025
Purpose of review: Provide the most up-to-date information on the dynamic landscape of antibody–drug conjugates (ADCs) in gynecologic cancers. We discuss the latest research that supports the approved ADCs and outline the ongoing trials and preliminary results that may lead to ADC approvals in the future. Current gaps in knowledge and areas for future research are discussed. Recent findings: ADCs are rapidly changing the landscape of gynecologic cancer care. Three ADCs are currently FDA approved and used routinely in clinical practice, with many more currently in clinical development. The most common ADC target is folate receptor alpha of which there are 8 different folate receptor targeting ADCs in development. Other targets under investigation include trophoblast cell surface antigen-2 (Trop-2), claudin-6 (CLDN6), cadherin-6 (CDH6), nectin-4, HER-2 and B7-H4. ADCs can cause new and unique adverse effects, including ocular toxicities and interstitial lung disease. Summary: ADCs offer the opportunity for a more effective and personalized treatment approach for gynecologic cancer patients. Side effects must be closely monitored, and preventive measures must be followed to maximize benefit and minimize toxicity. A better understanding of the role of target proteins as biomarkers to predict response to ADCs will be critical for successful clinical implementation of ADCs and further research in this area is necessary.
- 4 November 2024
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 37 (1) , 5-15
Open AccessAntibody–drug conjugates as targeted therapy for treating gynecologic cancers: update 2025
Purpose of review: Provide the most up-to-date information on the dynamic landscape of antibody–drug conjugates (ADCs) in gynecologic cancers. We discuss the latest research that supports the approved ADCs and outline the ongoing trials and preliminary results that may lead to ADC approvals in the future. Current gaps in knowledge and areas for future research are discussed. Recent findings: ADCs are rapidly changing the landscape of gynecologic cancer care. Three ADCs are currently FDA approved and used routinely in clinical practice, with many more currently in clinical development. The most common ADC target is folate receptor alpha of which there are 8 different folate receptor targeting ADCs in development. Other targets under investigation include trophoblast cell surface antigen-2 (Trop-2), claudin-6 (CLDN6), cadherin-6 (CDH6), nectin-4, HER-2 and B7-H4. ADCs can cause new and unique adverse effects, including ocular toxicities and interstitial lung disease. Summary: ADCs offer the opportunity for a more effective and personalized treatment approach for gynecologic cancer patients. Side effects must be closely monitored, and preventive measures must be followed to maximize benefit and minimize toxicity. A better understanding of the role of target proteins as biomarkers to predict response to ADCs will be critical for successful clinical implementation of ADCs and further research in this area is necessary.